[Safety of tadalafil in patients with cardiovascular comorbidities]

Urologiia. 2019 Apr;(1):119-124.
[Article in Russian]


Tadalafil is a drug from the phosphodiesterase-5 inhibitors (PDE-5) group, which is used to treat erectile dysfunction (ED), lower urinary tract symptoms (LUTS) caused by benign prostatic hyperplasia (BPH) and ED with LUTS in patients with BPH. The efficacy and safety of tadalafil were reviewed. The focus was on cardiovascular safety of tadalafil due to frequent cardiovascular comorbidities in patients with ED. We concluded that tadalafil is well tolerated and safe in patients with cardiovascular comorbidities and, in addition, has a beneficial effect on the cardiovascular system.

Keywords: cardiovascular pathology; cardiovascular safety; erectile dysfunction; phosphodiesterase-5 inhibitors; tadalafil.

MeSH terms

  • Cardiovascular Diseases* / complications
  • Cardiovascular System* / drug effects
  • Erectile Dysfunction* / complications
  • Erectile Dysfunction* / drug therapy
  • Humans
  • Lower Urinary Tract Symptoms* / complications
  • Lower Urinary Tract Symptoms* / drug therapy
  • Male
  • Phosphodiesterase 5 Inhibitors / adverse effects
  • Phosphodiesterase 5 Inhibitors / therapeutic use
  • Prostatic Hyperplasia / complications
  • Tadalafil* / adverse effects
  • Tadalafil* / therapeutic use
  • Treatment Outcome


  • Phosphodiesterase 5 Inhibitors
  • Tadalafil